Tag:
THE LIBRARY: WHITEPAPER
Mitigating Phase 2 Development Risks
Phase 2 is the end of the road for many molecules and for others the source of later delays and denials. Learn techniques for mitigating the risks that threaten your development program in the new white paper, Mitigating Phase 2 Development Risks: Design and Operational Strategies and Case Studies for Phase 2 Success. Download the white paper today!
EVENTS
- FierceBiotech Executive Breakfast: Fast Phase IIIs October 21, 2014 — Boston, MA — Sponsored by Covance and INC Research
- BioBasics: Biotech for the Non-ScientistOctober 23-24 — Boston, MA
- Drug Development Boot Camp - November 19-20, 2014, Boston, MANovember 19-20, 2014 — Boston, MA — Hosted by Harvard University OTD and Speid & Associates, Inc.
Press Releases
- Center for Advanced Cellular Therapeutics to Rise on Penn Medicine Campus
- Trialbee Helps AstraZeneca Reduce the Time Required for Recruitment of Patients to Clinical Trials
- RNA Therapeutics Market is Expected to Reach $1.2 Billion, Globally, by 2020- Allied Market Research
- Compound protects brain cells after traumatic brain injury
- UT Southwestern researchers discover novel class of NAMPT activators for neurodegenerative disease; Calico enters into exclusive collaboration with 2M to develop UTSW technology
- More Press Releases
Sponsored Links